GlaxoSmithKline Pakistan Limited informed Pakistan Stock Exchange about Based on the information received and correspondence with regulatory authorities, GSK made the decision in September 2019 and extended it in October 2019, to initiate a voluntary pharmacy/retail level recall in all markets of Zantac products manufactured using all API sources, as a precautionary action. The recall also applied to all Zantac products manufactured in Pakistan.

The announcement is available at:

https://dps.psx.com.pk/download/document/147930.pdf

GlaxoSmithKline Pakistan Limited (the Company) is incorporated in Pakistan as a limited liability company. It is engaged in manufacturing and marketing of research based ethical specialties and pharmaceutical products. The Company is a subsidiary of S.R. One International B.V., incorporated in Netherlands, whereas its ultimate parent company is GlaxoSmithKline plc, UK (GSK plc).

© Pakistan Press International, source Asianet-Pakistan